Suma M. Krishnan is a distinguished figure in the biotechnology industry, currently serving as the President of Research and Development at KRYSTAL BIOTECH INC. With a robust background in biopharmaceuticals, Krishnan has over two decades of experience in leading R&D initiatives, particularly in the development of novel therapies for rare diseases. Prior to joining KRYSTAL BIOTECH, she held significant roles at major companies such as Genentech and Amgen, where she spearheaded numerous drug development programs from early-stage research through to clinical trials. At KRYSTAL BIOTECH, Krishnan plays a pivotal role in steering the company's strategic direction in research and development. Her leadership has been instrumental in advancing the company's pipeline, notably with the development of their flagship product, a gene therapy aimed at treating a rare skin disorder. Under her guidance, KRYSTAL BIOTECH has made significant strides in clinical research, achieving several regulatory milestones and forging key partnerships to further their mission. Krishnan's expertise in navigating the complex landscape of biopharma R&D has been a driving force behind the company's success in bringing innovative treatments to patients in need. Krishnan's contributions to the field extend beyond her corporate roles. She is an active member of several professional organizations and frequently speaks at industry conferences, sharing insights on the latest advancements in gene therapy and rare disease treatments. Her dedication to advancing medical science, coupled with her strategic vision, makes her an invaluable asset to KRYSTAL BIOTECH and the broader biopharmaceutical community.